STOCK TITAN

Innate Pharma - IPHA STOCK NEWS

Welcome to our dedicated news page for Innate Pharma (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Innate Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Innate Pharma's position in the market.

Rhea-AI Summary
Innate Pharma announces presentations at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
Rhea-AI Summary
Innate Pharma releases its total number of shares and voting rights
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
none
-
Rhea-AI Summary
Innate Pharma announces partial clinical hold on lacutamab trials due to fatal case of rare disorder
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
Rhea-AI Summary
Interim efficacy results confirm clinical activity and favorable safety profile of lacutamab in advanced Mycosis Fungoides
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
clinical trial
-
Rhea-AI Summary
Innate Pharma reports positive clinical data for ANKET® NK cell engager and grants exclusive rights to Takeda for ADC development. Cash position of €124.7 million as of June 30, 2023. New Chief Medical Officer appointed. Final results from Phase 2 trial expected in H2 2023. FDA Fast Track Designation received. $5m upfront payment to Innate and up to $410m in future milestones plus royalties. Conference call scheduled for today.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
earnings
-
Rhea-AI Summary
Innate Pharma to participate in investor conferences and hold conference call to give business update on September 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
none
Rhea-AI Summary
Innate Pharma has announced the initiation of the Phase 2 MATISSE trial, evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi and chemotherapy in early stage lung cancer. The primary objectives of the study are to assess antitumor activity and safety. The trial is conducted in collaboration with AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
clinical trial
Innate Pharma

Nasdaq:IPHA

IPHA Rankings

IPHA Stock Data

192.40M
30.48M
0.1%
0.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
France
Marseille

About IPHA

innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma